Stewart W. Strong - May 17, 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
President, Global Hospital
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Strong
Stock symbol
HAE
Transactions as of
May 17, 2024
Transactions value $
-$113,509
Form type
4
Date filed
5/21/2024, 06:01 PM
Previous filing
May 17, 2024
Next filing
May 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Tax liability -$27.2K -284 -1.82% $95.73 15.3K May 17, 2024 Direct F1, F2
transaction HAE Common Stock Award +2.87K +18.74% 18.2K May 17, 2024 Direct F2, F3, F4
transaction HAE Common Stock Options Exercise $127K +2.24K +12.32% $56.57 20.4K May 20, 2024 Direct F2, F5
transaction HAE Common Stock Tax liability -$148K -1.56K -7.61% $95.08 18.9K May 20, 2024 Direct F2, F5, F6
transaction HAE Common Stock Sale -$65.2K -686 -3.63% $95.11 18.2K May 20, 2024 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +6.31K $0.00 6.31K May 17, 2024 Common Stock 6.31K $95.73 Direct F7
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -2.24K -49.99% $0.00 2.24K May 20, 2024 Common Stock 2.24K $56.57 Direct F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2 This number includes unvested RSUs previously reported.
F3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F5 Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).
F6 Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
F7 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
F8 Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.